Supplementary Figure 2 from Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine

Autor: Stephen Jones, Joanne L. Blum, Silke Hoersch, Carrie Brownstein, Kristi McIntyre, Robert Brooks, Ragene Rivera, Scot Sedlacek, Deborah Lindquist, Svetislava Vukelja, Frankie Ann Holmes, Lea Krekow, John Pippen, Christopher Stokoe, Devchand Paul, Mark R. Lackner, Yuanyuan Xiao, Hartmut Koeppen, Joyce O'Shaughnessy

Figure S2: Distribution of central Ki-67 scores in (A) ER-positive/HER2-negative breast cancer (n=824) and (B) TNBC (n=454)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d27d672ffe281528bd28900935eb2264
https://doi.org/10.1158/1078-0432.22459088

Supplementary Tables S1-5 from Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine

Autor: Stephen Jones, Joanne L. Blum, Silke Hoersch, Carrie Brownstein, Kristi McIntyre, Robert Brooks, Ragene Rivera, Scot Sedlacek, Deborah Lindquist, Svetislava Vukelja, Frankie Ann Holmes, Lea Krekow, John Pippen, Christopher Stokoe, Devchand Paul, Mark R. Lackner, Yuanyuan Xiao, Hartmut Koeppen, Joyce O'Shaughnessy

Supplementary Tables S1-5. Table S1. Baseline demographic and disease characteristics of patients with central Ki-67 data available. Table S2. Concordance between central and local Ki-67 scores. Table S3. Percentage of patients with a DFS event or de

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba8b1b4c0a02880f2887e7587f35652a
https://doi.org/10.1158/1078-0432.22459082.v1

Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML)

Autor: David A. Sallman, Daniel J. DeAngelo, Naveen Pemmaraju, Shira Dinner, Saar Gill, Rebecca L. Olin, Eunice S. Wang, Marina Konopleva, Eileen Stark, Ana Korngold, Asifa Haider, Kate Backhouse, Carolyn Figliola, Daniel J. Lee, Mark G. Frattini, Carrie Brownstein, Gail J. Roboz

Publikováno v: Blood. 140:2371-2373

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bb90f24e6eaf0604eb09bba5e0f7c12b
https://doi.org/10.1182/blood-2022-169928

Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration

Autor: Andrew Dj, Pearson, Claudia, Rossig, Crystal, Mackall, Nirali N, Shah, Andre, Baruchel, Gregory, Reaman, Rosanna, Ricafort, Delphine, Heenen, Abraham, Bassan, Michael, Berntgen, Nick, Bird, Eric, Bleickardt, Najat, Bouchkouj, Peter, Bross, Carrie, Brownstein, Sarah Beaussant, Cohen, Teresa, de Rojas, Lori, Ehrlich, Elizabeth, Fox, Stephen, Gottschalk, Linda, Hanssens, Douglas S, Hawkins, Ivan D, Horak, Danielle H, Taylor, Courtney, Johnson, Dominik, Karres, Franca, Ligas, Donna, Ludwinski, Maksim, Mamonkin, Lynley, Marshall, Behzad K, Masouleh, Yousif, Matloub, Shannon, Maude, Joe, McDonough, Veronique, Minard-Colin, Koen, Norga, Karsten, Nysom, Alberto, Pappo, Laura, Pearce, Rob, Pieters, Martin, Pule, Alfonso, Quintás-Cardama, Nick, Richardson, Martina, Schüßler-Lenz, Nicole, Scobie, Martina A, Sersch, Malcolm A, Smith, Jaroslav, Sterba, Sarah K, Tasian, Brenda, Weigel, Susan L, Weiner, Christian Michel, Zwaan, Giovanni, Lesa, Gilles, Vassal

Publikováno v: European journal of cancer
European journal of cancer, 160:112-133

The seventh multi-stakeholder Paediatric Strategy Forum focused on chimeric antigen receptor (CAR) T-cells for children and adolescents with cancer. The development of CAR T-cells for patients with haematological malignancies, especially B-cell precu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::7e4b2ff665e9b497893f3198ef4554c2
https://repository.uantwerpen.be/docstore/d:irua:12922

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure

Autor: Moshe Talpaz, Carrie Brownstein, Tymara Berry, Juan Shen, Eric Jourdan, Srdan Verstovsek, Nicolaas Schaap, Claire N. Harrison, Harry C. Schouten, Richard T. Silver, Shelonitda Rose, Ruben A. Mesa, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Sonja Zweegman, Francesco Passamonti

Publikováno v: American Journal of Hematology, 95(6), 594-603. Wiley
American Journal of Hematology, 95, 594-603
American Journal of Hematology
Harrison, C N, Schaap, N, Vannucchi, A M, Kiladjian, J J, Jourdan, E, Silver, R T, Schouten, H C, Passamonti, F, Zweegman, S, Talpaz, M, Verstovsek, S, Rose, S, Shen, J, Berry, T, Brownstein, C & Mesa, R A 2020, ' Fedratinib in patients with myelofibrosis previously treated with ruxolitinib : An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure ', American Journal of Hematology, vol. 95, no. 6, pp. 594-603 . https://doi.org/10.1002/ajh.25777
American Journal of Hematology, 95, 6, pp. 594-603
American Journal of Hematology, 95(6), 594-603. Wiley-Liss Inc.

Contains fulltext : 220650.pdf (Publisher’s version ) (Open Access) Fedratinib is an oral, selective Janus kinase 2 (JAK2) inhibitor. The phase II JAKARTA2 study assessed fedratinib in patients with intermediate- or high-risk myelofibrosis (MF) who

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58c760202f3ed0846e8d53c2418d1bb1
https://cris.maastrichtuniversity.nl/en/publications/ab793601-9c16-42c0-9fb3-e453a23756e7